STAREE
2026
STAtin Therapy for Reducing Events in the Elderly
In 9,971 healthy adults aged 70 years or over, atorvastatin 40 mg improved one of two co-primary outcomes disability-free survival and major cardiovascular events compared with placebo.
Result
Efficacy: Co-primary: (1) disability-free survival, defined as survival free of dementia and persistent physical disability; (2) major cardiovascular events (cardiovascular death, non-fatal myocardial infarction or stroke; registry definition also lists coronary revascularisation)HR 0.70 (95% CI 0.61-0.82) · P < 0.001
Below 1 favours atorvastatin 40 mg, above 1 favours placebo.
- Absolute difference
- 2.3 points
- NNT
- 44
Absolute difference and NNT are derived from the event rates.
Also reported: The other co-primary, disability-free survival, was unchanged: 12.8% vs 13.6% (HR 0.94, 95% CI 0.84-1.05; P = 0.25). Muscle, liver and diabetes-related adverse events were more common with atorvastatin; serious adverse events 2.7% in both arms.
- Subtopic
- Primary prevention
- Design
- Double-blind, placebo-controlled RCT, 1:1, recruited through Australian general practice, average follow-up about 6 years planned, time-to-first-event analyses for each co-primary endpoint
- Relevance
- Practice-defining: a trial the field needs to know.
- Source
- Zoungas S, et al. N Engl J Med. 2026; published online 28 August.doi 10.1056/nejmoa2607314
Discussion & critique
The trial general practice has been waiting for: a statin started after 70, in people without cardiovascular disease, diabetes or dementia. Cardiovascular events fall by 30% relative and 2.3 percentage points absolute over six years, roughly 43 people treated for one event avoided. The endpoint older patients are usually promised, years free of dementia and disability, did not move, and the entrants were healthy volunteers rather than the frail, comorbid 80-year-olds in whom the question is hardest.